| Objective To investigate the expression of positive pentameric protein 3(PTX3) and tissue factor pathway inhibitor(TFPI in serum of patients with ulcerative colitis(UC) and its clinical significance. Methods A total of 157 UC patients admitted to the Affiliated Hospital of North China University of Science and Technology from July 2020 to May 2022 were selected as the observation group.They were divided into the remission group(Mayo score 0~2, n=62) and the active group(Mayo score ≥ 3, n=95) according to Mayo scores.Active patients were divided into a mild group(32 cases), a moderate group(40 cases), and a severe group(23 cases) according to their condition. According to the prognosis of patients, the observation group was divided into an improved group(n=108) and a non-improved group(n=49).Enzyme-linked immunosorbent assay(ELISA) was used to detect the serum PTX3 and TFPI levels before and after treatment.ROC curve was performed to analyze the diagnostic value of serum PTX3 and TFPI before treatment in patients with UC who did not improve after clinical treatment. Results Before treatmentthe serum PTX3 and TFPI levels in the remission stage group were(8.56±2.35) ng/mL and(85.42±9.62) ng/mL respectively, which were lower than those in the active stage group respectively, with statistically significant differences(P<0.05).The difference in PTX3, TFPI before and after treatment between the remission group and the active group was statistically significant(P<0.05).During the active period, the serum levels of PTX3, TFPI in the moderate and severe groups before treatment were higher than those in the mild group. The serum levels of PTX3 and TFPI in the severe group before treatment were higher than those in the moderate group, and the difference was statistically significant(P<0.05).The serum levels of PTX3 and TFPI in UC patients in the non improvement group were higher than those in the improvement group, and the difference was statistically significant(P<0.05).The areas under the curve of untreated patients with UC diagnosed by serum PTX3 and TFPI alone and in combination before treatment were 0.830(95% CI=0.762~0.885), 0.819(95% CI=0.749~0.876), and 0.907(95% CI=0.851~0.948), respectively. Conclusions The serum levels of PTX3 and TFPI increase in UC patients, which is related to the severity and prognosis of the patients, and may be used as markers for the evaluation of the disease and efficacy of UC patients. |
